DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for endometrium carcinoma in situ — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEndometrium carcinoma in situ maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for endometrium carcinoma in situ is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractThe evidence concerning those factors related to prognosis in endometrial carcinoma has been reviewed and age, histologic differentiation of the tumor, depth of myometrial invasion and extent of disease have been found to be definitely correlated with survival. The development of different treatment methods has been traced and various modern treatment techniques have been discussed. On the basis of these prognostic indicators and reported experience with alternative methods of therapy, a plan of management for patients with endometrial carcinoma has been proposed. Although we believe this is a logical method with proven effectiveness, we wish to emphasize the importance of individualized therapy based on an understanding of the clinical-pathological findings.
Postoperative irradiation in carcinoma of the endometrium
AbstractSurvival following treatment for carcinoma of the endometrium was evaluated in 761 women. An unexpected finding was a higher 5-year relative survival ratio for women who received radiation therapy following hysterectomy than for those who had hysterectomy without subsequent radiotherapy. This difference in survival rates was most pronounced in women with tumors confined to the corpus uteri but with unfavorable nuclear grades.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
